Research Banner Thierry

About us

The Oxford Parkinson's Disease Centre (OPDC) is a unique multidisciplinary research centre at the University of Oxford supported by Parkinson’s UK with funds from The Monument Trust, one of the Sainsbury Family Charitable Trusts.

Established in February 2010, the Oxford Parkinson’s Disease Centre (OPDC) brings together internationally-renowned scientists who work on the genetics of Parkinson’s, the generation of cell and animal models, and the wiring of brain circuits which control movement, with clinical experts in the diagnosis and treatment of Parkinson’s.

Our world-class research centre was formed to understand the earliest events in the development of Parkinson’s and create animal models with greater relevance to the disease, ultimately with a view to identifying the changes which occur before the symptoms become apparent.

Our programme targets the molecular pathways to Parkinson’s in order to:

  1. Understand the progression of Parkinson’s
  2. Predict the onset of Parkinson’s
  3. Identify potential drug targets for Parkinson’s
  4. Develop new treatments that will prevent the development of Parkinson’s in at-risk individuals.
  • Watch the video below to learn more about OPDC's research

 

Selected Publications

News

OPDC scientist Dr Ludovica Griffanti talks about her research in the pub at sell-out event

OPDC scientist Dr Ludovica Griffanti talks about her research in the pub at sell-out event

Posted 24/05/2017

This May, Dr Ludovica Griffanti was among scientists who spoke at the sell-out Beautiful Minds session at the St Aldates Tavern, Oxford. The event was part of the Pint of Science series which brings some of the most brilliant scientists to local pubs to discuss their latest research and findings. Dr Griffanti is a researcher with OPDC at the Oxford Centre for Functional Magnetic Resonance Imaging of the Brain (FMRIB). Her talk dealt with her ...


Mission Therapeutics and OPDC PI Richard Wade-Martins awarded research grant from the Michael J. Fox Foundation

Mission Therapeutics and OPDC PI Richard Wade-Martins awarded research grant from the Michael J. Fox Foundation

Posted 11/04/2017

Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat neurodegenerative diseases, cancer and other diseases with high unmet medical need, announced that it has been awarded a grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF). This research grant, announced on World Parkinson’s day, will support the testing of Mission Therapeutics’ potent ...


OPDC Investigator heads up new consortium to investigate aggregated proteins in Alzheimer’s and Parkinson’s

OPDC Investigator heads up new consortium to investigate aggregated proteins in Alzheimer’s and Parkinson’s

Posted 10/04/2017

The Innovative Medicines Initiative (IMI) launched IMPRiND in March 2017, an innovative research project that is devoted to investigating whether mechanisms of propagation of aggregated proteins between cells could enable novel therapeutic approaches in Alzheimer’s and Parkinson’s. Alzheimer’s and Parkinson’s are age-related neurodegenerative disorders without cure. They are characterised by the progressive loss of brain cells often along ...

Click here to sign up to the OPDC News Mailing list

Seminars/Events

Steven Finkbeiner 13 June 2017

Steven Finkbeiner 13 June 2017

Posted 30/09/2016

Professor Steven Finkbeiner, M.D., Ph.D. is a neurologist and neuroscientist, a professor at the University of California, San Francisco, and associate director at the Gladstone Institutes. He directs an academic research laboratory focused on neurodegenerative diseases and mental illnesses and directs the Taube/Koret Center for Neurological Disease, which focuses on collaborating with industry to develop neurotherapeutics. Dr. Finkbeiner ...

Michela Deleidi July 4 2017

Michela Deleidi July 4 2017

Posted 19/09/2016

Dr. Deleidi group’s research aims to identify key molecular pathways in the pathogenesis of sporadic and familial Parkinson's using human neurons derived from induced pluripotent stem cells (iPSCs). Michela Deleidi is studying human ageing processes and age-related neurological disorders with a particular focus on Parkinson's. She wants to employ stem cells from people affected by the condition and investigate how the immune system and ...

Med Sci
OUH TrustBRC logoNIHR